ORIGINAL ARTICLE
Podoplanin expression in salivary gland carcinomas and its clinical significance. An immunohistochemical study
1
Oral Pathology, Faculty of Dentistry, Mansoura University, Mansoura, Egypt
2
Pathology Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt
3
Department of Basic Medical Sciences, College of Medicine, AlMaarefa University, Riyadh, Saudi Arabia
4
Medical Oncology, Faculty of Medicine, Mansoura University, Mansoura, Egypt
5
Oral Pathology, Faculty of Dentistry, Technology and Maritime Transport, Arab Academy for Science, Egypt
Submission date: 2022-06-23
Acceptance date: 2022-11-28
Publication date: 2023-03-20
Corresponding author
Heba Sheta
Heba Sheta Pathology Department Faculty of Medicine Mansoura University El-Gomhouria Street Mansoura City Dakahlia, Egypt
Heba Sheta Pathology Department Faculty of Medicine Mansoura University El-Gomhouria Street Mansoura City Dakahlia, Egypt
Pol J Pathol 2022;73(4):320-329
KEYWORDS
TOPICS
ABSTRACT
Podoplanin (D2-40) is a lymphatic endothelial marker that is considered as a specific marker for lymphatic endothelial cells and lymphangiogenesis in salivary gland carcinomas (SGCs). Aim: the present study aimed to investigate the immunohistochemical expression of podoplanin in SGCs and to correlate its expression with the clinicopathological parameters and patients’ survival.
Forty-nine SGC cases were electronically selected. Demographic, clinical, laboratory, and survival data were reviewed and tabulated. Immunohistochemistry was performed using antipodoplanin. Cases were divided into low and high expression based on a scoring system. A score of 0 and 1 was considered low expression, while > 1 was considered high expression.
Podoplanin high expression was seen in 46.9% of cases, and 53.1% of cases showed low expression. Significant statistical associations were seen between podoplanin expression and tumour grade ( p ≤ 0.001), tumour-nodal- metastasis (TNM) stage (p ≤ 0.001), tumour size (p ≤ 0.001), nodal metastasis (p ≤ 0.001), tumour type (p = 0.03), prognosis (p ≤ 0.001), and mortality (p ≤ 0.001). The overall survival and progression-free survival differed significantly in cases with high and low expression (p ≤ 0.001).
Podoplanin overexpression might be a significant prognostic indicator for patients with SGCs, implicating that it is a potential therapeutic target to improve survival in these cancer patients.
Forty-nine SGC cases were electronically selected. Demographic, clinical, laboratory, and survival data were reviewed and tabulated. Immunohistochemistry was performed using antipodoplanin. Cases were divided into low and high expression based on a scoring system. A score of 0 and 1 was considered low expression, while > 1 was considered high expression.
Podoplanin high expression was seen in 46.9% of cases, and 53.1% of cases showed low expression. Significant statistical associations were seen between podoplanin expression and tumour grade ( p ≤ 0.001), tumour-nodal- metastasis (TNM) stage (p ≤ 0.001), tumour size (p ≤ 0.001), nodal metastasis (p ≤ 0.001), tumour type (p = 0.03), prognosis (p ≤ 0.001), and mortality (p ≤ 0.001). The overall survival and progression-free survival differed significantly in cases with high and low expression (p ≤ 0.001).
Podoplanin overexpression might be a significant prognostic indicator for patients with SGCs, implicating that it is a potential therapeutic target to improve survival in these cancer patients.
REFERENCES (39)
1.
Ansari MH. Salivary gland tumors in an Iranian population: a retrospective study of 130 cases. J Oral Maxillofac Sur 2007; 65: 2187-2194.
2.
Jones A, Craig G, Speight P, Franklin C. The range and demographics of salivary gland tumours diagnosed in a UK population. Oral Oncol 2008; 44: 407-417.
3.
Murase R, Sumida T, Ishikawa A, et al. Novel therapeutic strategies for malignant salivary gland tumors: lessons learned from breast cancer. Int J Otolaryngol 2011; 2011: 187623.
4.
Neville BW, Damm DD, Allen CM, et al. Oral and maxillofacial pathology, (4th ed): Elsevier Health Sciences 2015.
5.
Deschler DG, Day T. TNM staging of head and neck cancer and neck dissection classification. American Academy of Otolaryngology – Head and Neck Surgery Foundation 2008, 10-23.
6.
Americo MG, Marques YMFS, Ankha MDVEA, et al. Correlation of intratumoral lymphatic microvessel density, vascular endothelial growth factor C and cell proliferation in salivary gland tumors. Med Mol Morphol 2017; 50: 17-24.
7.
Bhattacharyya N, Fried MP. Nodal metastasis in major salivary gland cancer: predictive factors and effects on survival. Arch Otolaryngol Head Neck Surg 2002; 128: 904-908.
8.
Yap TA, Lorente D, Omlin A, Olmos D, et al. Circulating tumor cells: a multifunctional biomarker. Clion Cancer Res 2014; 20: 2553-2568.
9.
Bai B, Ma W, Wang K, et al. Detection of D2-40 monoclonal antibody-labeled lymphatic vessel invasion in esophageal squamous cell carcinoma and its clinicopathologic significance. Cancer Biol Med 2013; 10: 81.
10.
Wicki A, Christofori G. The potential role of podoplanin in tumour invasion. Br J Cancer 2007; 96: 1-5.
11.
Seethala R. An update on grading of salivary gland carcinomas. Head Neck Pathol 2009; 3: 69-77.
12.
Deschler DG, Moore MG, Smith RV. Quick reference guide to TNM staging of head and neck cancer and neck dissection classification. In: Alexandria VA American Academy of Otolaryngology – Head and Neck Surgery Foundation 2014, (4th ed).
13.
Wu HM, Ren GX, Wang LZ, et al.. Expression of podoplanin in salivary gland adenoid cystic carcinoma and its association with distant metastasis and clinical outcomes. Mol Med Rep 2012; 6: 271-274.
14.
Siegel RL, Miller KD, Jemal A. Cancer statistics. CA Cancer J Clin 2020; 70: 7-30.
15.
Astarita JL, Cremasco V, Fu J, et al. The CLEC-2-podoplanin axis controls the contractility of fibroblastic reticular cells and lymph node microarchitecture. Nat Immunol 2015; 16: 75-84.
16.
Quintanilla M, Montero-Montero L, Renart J, et al. Podoplanin in inflammation and cancer. Int J Mol Sci 2019; 20: 707.
17.
Krishnan H, Miller WT, Blanco FJ, et al. Src and podoplanin forge a path to destruction. Drug Discov Today 2019; 24: 241-249.
18.
Acton SE, Astarita JL, Malhotra D, et al. Podoplanin-rich stromal networks induce dendritic cell motility via activation of the C-type lectin receptor CLEC-2. Immunity 2012; 37: 276-289.
19.
Herzog BH, Fu J, Wilson SJ, et al. Podoplanin maintains high endothelial venule integrity by interacting with platelet CLEC-2. Nature 2013; 502: 105-109.
20.
Krishnan H, Rayes J, Miyashita T, et al. Podoplanin: an emerging cancer biomarker and therapeutic target. Cancer Sci 2018; 109: 1292-1299.
21.
Zhou Q, Wang Z, Zeng H, et al. Identification and validation of poor prognosis immunoevasive subtype of muscle-invasive bladder cancer with tumor-infiltrating podoplanin+ cell abundance. Oncoimmunology 2020; 9: 1747333.
22.
Suzuki J, Aokage K, Neri S, et al. Relationship between podoplanin expressing cancer-associated fibroblasts and the immune microenvironment of early lung squamous cell carcinoma. Lung Cancer 2021; 153: 1-10.
23.
Bieniasz-Krzywiec P, Martin-Perez R, Ehling M, et al. Podoplanin-expressing macrophages promote lymphangiogenesis and lymphoinvasion in breast cancer. Cell Metab 2019; 30: 917-936.e10.
24.
Yoshida T, Ishii G, Goto K, et al. Podoplanin-positive cancer- associated fibroblasts in the tumor microenvironment induce primary resistance to EGFR-TKIs in lung adenocarcinoma with EGFR mutation. Clin Cancer Res 2015; 21: 642-651.
25.
Nakamura H, Sugano M, Miyashita T, et al. Organoid culture containing cancer cells and stromal cells reveals that podoplanin-positive cancer-associated fibroblasts enhance proliferation of lung cancer cells. Lung Cancer 2019; 134: 100-107.
26.
Kawaguchi H, El-Naggar AK, Papadimitrakopoulou V, et al. Podoplanin: a novel marker for oral cancer risk in patients with oral premalignancy. J Clin Oncol 2008; 26: 354-360.
27.
Retzbach EP, Sheehan SA, Nevel EM, et al. Podoplanin emerges as a functionally relevant oral cancer biomarker and therapeutic target. Oral Oncol 2018; 78: 126-136.
28.
Chopra S, Deodhar K, Pai V, et al. Cancer stem cells, CD44, and outcomes following chemoradiation in locally advanced cervical cancer: results from a prospective study. Int J Radiat Oncol Biol Phys 2019; 103: 161-168.
29.
Monteiro LS, Delgado ML, Ricardo S, et al. Prognostic significance of CD44v6, p63, podoplanin and MMP-9 in oral squamous cell carcinomas. Oral Dis 2016; 22: 303-312.
30.
Bartuli FN, Luciani F, Caddeo F, et al. Podoplanin in the development and progression of oral cavity cancer: a preliminary study. Oral Implantol 2012; 5: 33-41.
31.
Barros FBA, Assao A, Garcia NG, et al. Moesin expression by tumor cells is an unfavorable prognostic biomarker for oral cancer. BMC Cancer 2018; 18: 53.
32.
Ugorski M, Dziegiel P, Suchanski J. Podoplanin — a small glycoprotein with many faces. Am J Cancer Res 2016; 6: 370-386.
33.
Ito T, Ishii G, Nagai K, et al. Low podoplanin expression of tumor cells predicts poor prognosis in pathological stage IB squamous cell carcinoma of the lung, tissue microarray analysis of 136 patients using 24 antibodies. Lung Cancer 2009; 63: 418-424.
34.
Ikoma Y, Kijima H, Masuda R, et al. Podoplanin expression is correlated with the prognosis of lung squamous cell carcinoma. Biomed Res 2015; 36: 393-402.
35.
Garcia AS, Assao A, Carvalho AL, et al. The stem cell markers expression CD44v6 and podoplanin in lip cancer: clinical significance. Virchows Arch 2019; 474: 745-754.
36.
Wang X, Wang X, Carvalho V, et al. Prognostic value of podoplanin in various tumors. Technol Cancer Res Treat 2021; 20: 1-10.
37.
Schacht V, Ramirez MI, Hong YK, et al. T1/podoplanin deficiency disrupts normal lymphatic vasculature formation and causes lymphedema. EMBO J 2003; 22: 3546-3556.
38.
Gleber-Netto FO, Flor˜ncio TNG, de Sousa SF, et al. Angiogenesis and lymphangiogenesis in mucoepidermoid carcinoma of minor salivary glands. J Oral pathol Med 2012; 41: 603-609.
39.
Dezfuli MK, Seyedmajidi M, Nafarzadeh S, et al. Angiogenesis and lymphangiogenesis in salivary gland adenoid cystic carcinoma and mucoepidermoid carcinoma. Asian Pac J Cancer Prev 2019; 20: 3547.
Share
RELATED ARTICLE
| eISSN: | 2084-9869 |
| ISSN: | 1233-9687 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
